Exome Asset Management LLC Makes New $5.27 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

Exome Asset Management LLC acquired a new position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 120,165 shares of the company's stock, valued at approximately $5,274,000. Structure Therapeutics comprises approximately 3.5% of Exome Asset Management LLC's investment portfolio, making the stock its 4th largest position. Exome Asset Management LLC owned 0.21% of Structure Therapeutics as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Franklin Resources Inc. boosted its stake in shares of Structure Therapeutics by 9.4% in the 3rd quarter. Franklin Resources Inc. now owns 706,106 shares of the company's stock valued at $30,991,000 after purchasing an additional 60,397 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Structure Therapeutics by 0.7% in the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock valued at $1,985,000 after buying an additional 312 shares during the period. Barclays PLC boosted its stake in Structure Therapeutics by 64.5% in the third quarter. Barclays PLC now owns 81,138 shares of the company's stock valued at $3,562,000 after acquiring an additional 31,815 shares during the last quarter. Nomura Asset Management Co. Ltd. grew its holdings in Structure Therapeutics by 35.6% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 29,429 shares of the company's stock worth $1,292,000 after acquiring an additional 7,719 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Structure Therapeutics during the 3rd quarter valued at $1,787,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Stock Performance

NASDAQ:GPCR traded down $0.46 on Friday, reaching $31.25. The company's stock had a trading volume of 499,739 shares, compared to its average volume of 787,025. Structure Therapeutics Inc. has a 1-year low of $26.61 and a 1-year high of $62.74. The business's 50-day moving average price is $36.32 and its two-hundred day moving average price is $39.18. The firm has a market cap of $1.79 billion, a PE ratio of -42.23 and a beta of -3.41.

Analyst Upgrades and Downgrades

GPCR has been the topic of several recent research reports. HC Wainwright initiated coverage on Structure Therapeutics in a research report on Wednesday, December 4th. They issued a "buy" rating and a $80.00 price target on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $65.00 target price on shares of Structure Therapeutics in a report on Monday, September 23rd. Finally, Morgan Stanley initiated coverage on Structure Therapeutics in a research note on Monday, September 23rd. They issued an "overweight" rating and a $118.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $85.67.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.